Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 14, 2012, Pages

  Nguyen, David N ^a   Mahon, Kerry P ^a   Chikh, Ghania ^b   Kim, Phillip ^c   Chung, Hattie ^a   Vicari, Alain P ^b   Love, Kevin T ^a   Goldberg, Michael ^a   Chen, Steve ^a   Krieg, Arthur M ^b   Chen, Jianzhu ^a   Langer, Robert ^a,c   Anderson, Daniel G ^a,c,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b PFIZER INC   (United States)

^c USA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cell; Drug delivery; High throughput screening; Innate immunity

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALPHA INTERFERON; IMIDAZOQUINOLINE DERIVATIVE; LIPID; LIPIDOID RNA NANOPARTICLE; MYELOID DIFFERENTIATION FACTOR 88; NANOPARTICLE; OLIGONUCLEOTIDE; OVALBUMIN; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DESIGN; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; INTERFERON TYPE I; LIPIDS; MEMBRANE GLYCOPROTEINS; MICE; MYELOID DIFFERENTIATION FACTOR 88; NANOPARTICLES; RNA; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 7;

MUS; ORTHOMYXOVIRIDAE;

EID: 84859455253     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1121423109     Document Type: Article

References (56)

1. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987-995. (Pubitemid 41057715)
2. Zhang SY, et al. (2007) Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 220:225-236.
3. Meyer T, Stockfleth E (2008) Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 17:1051-1065.
4. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11(Suppl 4):S63-68. (Pubitemid 40562305)
5. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552-559. (Pubitemid 46830615)
6. Heil F, et al. (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529. (Pubitemid 38314424)
7. Schon MP, Schon M (2008) TLR7 and TLR8 as targets in cancer therapy. Oncogene 27:190-199.
8. Hornung V, et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263-270. (Pubitemid 40460553)
9. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31:3388-3393. (Pubitemid 33100532)
10. Borden EC, et al. (2007) Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975-990. (Pubitemid 350201788)
11. Akira S, Takeda K (2004) Functions of toll-like receptors: Lessons from KOmice. C R Biol 327:581-589. (Pubitemid 38979508)
12. Cristofaro P, Opal SM (2006) Role of Toll-like receptors in infection and immunity: Clinical implications. Drugs 66:15-29. (Pubitemid 43144961)
13. Honda K, Taniguchi T (2006) IRFs: Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6:644-658. (Pubitemid 44298214)
14. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419-426. (Pubitemid 47509552)
15. Delgado MF, et al. (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34-41.
16. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6:823-835.
17. Romagne F (2007) Current and future drugs targeting one class of innate immunity receptors: The Toll-like receptors. Drug Discov Today 12:80-87.
18. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-1531. (Pubitemid 38314425)
19. Lan T, et al. (2007) Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci USA 104:13750-13755. (Pubitemid 350003392)
20. Scheel B, et al. (2006) Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 36:2807-2816. (Pubitemid 44608463)
21. Eberle F, et al. (2008) Modificationsin small interfering RNA that separate immunostimulation from RNA interference. J Immunol 180:3229-3237.
22. Sioud M (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348:1079-1090.
23. Nguyen DN, et al. (2009) Drug delivery-mediated control of RNA immunostimulation. Mol Ther 17:1555-1562.
24. Robbins M, et al. (2008) Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19:991-999.
25. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2010) Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267:9-21.
26. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129-138.
27. Akinc A, et al. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26:561-569. (Pubitemid 351668042)
28. Nguyen DN, et al. (2009) A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery. Biotechnol Bioeng 103:664-675.
29. Forsbach A, et al. (2008) Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 180:3729-3738.
30. Semple SC, et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172-176.
31. Barchet W, et al. (2005) Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur J Immunol 35:236-242. (Pubitemid 40123870)
32. Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, Fitzgerald-Bocarsly P (2004) Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol 75:504-514. (Pubitemid 38316382)
33. Davila E, Celis E (2000) Repeated administration of cytosine- phosphorothiolated guanine- containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 165:539-547. (Pubitemid 30429549)
34. Halperin SA, et al. (2006) Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24:20-26. (Pubitemid 41721097)
35. Vollmer J, Krieg AM (2009) Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61:195-204.
36. Malyala P, O'Hagan DT, Singh M (2009) Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev 61:218-225.
37. Wilson KD, de Jong SD, Tam YK (2009) Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev 61:233-242.
38. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW (2008) CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 46:1310-1314. (Pubitemid 351589919)
39. Schlee M, Hornung V, Hartmann G (2006) siRNA and isRNA: Two edges of one sword. Mol Ther 14:463-470. (Pubitemid 44296098)
40. Sioud M (2007) RNA interference and innate immunity. Adv Drug Deliv Rev 59:153-163.
41. Weinstein S, Peer D (2010) RNAi nanomedicines: Challenges and opportunities within the immune system. Nanotechnology 21:232001.
42. Putnam D (2006) Polymers for gene delivery across length scales. Nat Mater 5:439-451.
43. Love KT, et al. (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107:1864-1869.
44. Mahon KP, et al. (2010) Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug Chem 21:1448-1454.
45. Asselin-Paturel C, Brizard G, Pin J-J, Briere F, Trinchieri G (2003) Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 171:6466-6477. (Pubitemid 37532075)
46. Jurk M, et al. (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3:499-499.
47. Gorden KK, et al. (2006) Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol 177:8164-8170. (Pubitemid 44846336)
48. Martinez J, Huang X, Yang Y (2010) Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA. Proc Natl Acad Sci USA 107:6442-6447.
49. Horsmans Y, et al. (2005) Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42:724-731. (Pubitemid 41233667)
50. Fidock MD, et al. (2011) The innate immune response, clinical outcomes,and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther 89:821-829.
51. Fletcher S, Steffy K, Averett D (2006) Masked oral prodrugs of toll-like receptor 7 agonists: A new approach for the treatment of infectious disease. Curr Opin Investig Drugs 7:702-708. (Pubitemid 44263174)
52. Savage P, et al. (1996) A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 74:1482-1486. (Pubitemid 26370744)
53. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 8:247-258. (Pubitemid 351432801)
54. Barr TA, Brown S, Mastroeni P, Gray D (2009) B cell intrinsic MyD88 signals drive IFN-gamma production from T cells and control switching to IgG2c. J Immunol 183:1005-1012.
55. Tritto E, Mosca F, De Gregorio E (2009) Mechanism of action of licensed vaccine adjuvants. Vaccine 27:3331-3334.
56. Chikh G, et al. (2009) Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol 21:757-767.